Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Bristol-Myers Squibb

Executive Summary

Bristol-Myers Squibb: Maxipime (cefepime) will be reviewed for treatment of febrile episodes in neutropenic patients March 5 by the Anti-Infective Drugs Advisory Committee at a meeting held at the Ramada Inn in Bethesda, Md. The open public hearing begins at 8:30. In the afternoon of March 5 and all of March 6 and 7, committee will discuss document to industry on evaluability criteria for review of anti-microbials at the Division of Anti-Infective Drug Products. Copies of the draft document can be obtained two weeks before the meeting by calling (301) 827-4573. On March 6 and 7, the meeting will be held at the Bethesda Holiday Inn...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029717

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel